Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 in hypertensive adults with type 2 diabetes mellitus
2011-000347-25Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change from baseline in HbA1c after 12 weeks of treatment and Change from baseline in mean 24-hour systolic blood pressure. Started Apr 2011; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on 2011-000347-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000347-25.